Sign In
Buy PCSA
$2.80
-0.120 (-4.11%)
At Close: Jun 03, 2026
Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)
01:28am, Monday, 27'th Apr 2026
Heatwurx (NASDAQ: PCSA - Get Free Report) and Stevanato Group (NYSE: STVN - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on
Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review
04:09am, Saturday, 04'th Apr 2026
Heatwurx (NASDAQ: PCSA - Get Free Report) and Aquestive Therapeutics (NASDAQ: AQST - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the tw
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
09:15am, Monday, 12'th Jan 2026
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today a
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
09:15am, Monday, 05'th Jan 2026
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company deve
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
10:26am, Thursday, 18'th Dec 2025
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?
01:10pm, Wednesday, 17'th Dec 2025
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
08:00am, Wednesday, 17'th Dec 2025
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
09:15am, Wednesday, 05'th Nov 2025
VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and inno
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
08:30am, Thursday, 07'th Aug 2025
VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for canc
Processa Pharmaceuticals Provides Portfolio and Business Update
09:00am, Tuesday, 01'st Jul 2025
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852 Continue enrolling patients in Phase 2 study of PCS6422 Strengthened balance sheet with $7M capital infus
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
12:26pm, Tuesday, 17'th Jun 2025
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (the “Company”), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) thera
HANOVER, Md., June 17, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), today announced that it has entered into a binding term sheet with Intact Therapeutics, Inc. (“Intact�
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
08:00am, Friday, 13'th Jun 2025
HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing Next Generation Cancer (NGC) therapies, today announce
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
09:00am, Friday, 30'th May 2025
HANOVER, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with im
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
08:00am, Tuesday, 15'th Apr 2025
HANOVER, Md., April 15, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next genera
